复星医药(600196.SH)：膦甲酸钠注射液药品获注册批准

Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of sodium foscarnet injection, expanding the company's product line [1] Group 1: Product Approval - The approved indications for the drug include treatment for (1) cytomegalovirus retinitis in AIDS patients and (2) acyclovir-resistant mucocutaneous infections in immunocompromised patients [1] Group 2: Business Impact - The approval of this drug will further enrich the product portfolio of the company, enhancing its market position in the pharmaceutical industry [1]